The company also added a ProteinSimple MFI 5200 micro-flow imaging system, a Wyatt Dawn Heleos II multi-angle laser light scattering (MALS) detector and a Wyatt DynaPro NanoStar dynamic light scattering (DLS) detector to support biopharma development services, as well as a ProteinSimple iCE3 capillary IEF to further support protein analyses.
AAIPharma also expanded its extractable and leachable (E&L) testing services to evaluate and qualify the materials used in the manufacturing process and final product configuration. New capabilities include a Foss Soxtec 2050 automated extraction system to enable reproducible and robust methodologies.
"AAIPharma specializes in comprehensive service offerings and offers the latest in instrumentation for our clients," said Patrick Walsh, chief executive officer of AAIPharma. "Since its grand opening, the Technology Center has been recognized for its modern, efficient operations and has exceeded client expectations as a world class laboratory."